Data Collection Study to Review Novel Methods for Diagnosing Obstructive Sleep Apnea
Launched by RESMED · Apr 9, 2025
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on finding new ways to diagnose obstructive sleep apnea (OSA), a condition where a person’s breathing stops and starts during sleep. Researchers will collect various types of data, including facial scans, videos of people speaking, blinking, and swallowing, as well as heart rate patterns. They want to see if any of these methods can help identify OSA more effectively than current methods.
To participate in the study, you need to be an adult aged 18 or older who can read and understand English. However, if you have already been diagnosed with OSA, have certain respiratory diseases, are pregnant or recently gave birth, or have a pacemaker, you won’t be eligible. Participants will help researchers gather important information, but this study is not yet recruiting, so it’s still in the planning stages. If you are interested in the study once it begins, it could contribute to better ways to diagnose OSA in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged \>= 18 Ability to read and comprehend English
- Exclusion Criteria:
- • Previous diagnosis of OSA
- • Respiratory diseases (such COPD, lung cancer, fibrosis of the lungs, lung injury)
- • Subjects who are or may be pregnant, breastfeeding or within 6 weeks postpartum (which may impact HRV temporarily)
- • Subjects with a pacemaker
About Resmed
ResMed is a global leader in developing innovative solutions for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic respiratory conditions. With a commitment to improving patient outcomes through advanced technology, ResMed specializes in cloud-connected devices and software that facilitate remote monitoring and management of respiratory health. The company’s clinical trials focus on evaluating the efficacy and safety of its products, enhancing treatment options, and advancing research in sleep and respiratory medicine. ResMed's dedication to evidence-based practices and patient-centered care positions it at the forefront of transforming healthcare delivery in respiratory therapy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported